3-D Matrix (7777) AI Stock Analysis

• Market Cap: ¥25.82B
• Dividend Yield: N/A
• Average Volume (3M): 3.62M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: 51.11%
• EPS Growth: -606.19%
• Country: JP
• Employees: 106
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -9.57
• Shares Outstanding: 112,277,275
• 10 Day Avg. Volume: 4,203,470
• 30 Day Avg. Volume: 3,621,283
• PEG Ratio: >-0.01
• Price to Book (P/B): 5.64
• Price to Sales (P/S): 1.80
• P/FCF Ratio: -7.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥238.86
• Price Target Upside: 4.76% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 51 Neutral
• Price Target: ¥239.00 ▲(4.82% Upside)

The stock's overall score is primarily impacted by its weak financial performance, characterized by consistent losses and high leverage. Despite strong technical indicators suggesting positive market momentum, the negative valuation metrics due to ongoing losses limit the stock's attractiveness. The absence of earnings call insights and corporate events further emphasizes the need for improved financial stability.

3-D Matrix Business Overview & Revenue Model

Company Description

3-D Matrix (7777) is a biotechnology company specializing in the development and commercialization of advanced biomaterials for medical applications. The company focuses on creating innovative solutions for tissue engineering and regenerative medicine, particularly through its proprietary 3D hydrogel technology. Its core products include bioactive scaffolds that support cell growth and tissue regeneration, catering to sectors such as orthopedics, wound healing, and drug delivery.

How the Company Makes Money

3-D Matrix generates revenue primarily through the sale of its biomaterials and hydrogel products to hospitals, research institutions, and pharmaceutical companies. The company has established key partnerships with medical device manufacturers and research organizations, allowing it to leverage collaborative projects and co-development agreements. Additionally, revenue is supplemented by licensing agreements for its proprietary technologies, which provide a continuous stream of income as well as potential royalties from future product developments. The company may also engage in government and private grants for research and development, further contributing to its earnings.

3-D Matrix Financial Statement Overview

Summary

3-D Matrix shows strong revenue growth but faces significant challenges with profitability and cash flow. The company has high leverage with a debt-to-equity ratio of 11.82 and a low equity base, indicating financial risk.

Income Statement

3-D Matrix has shown a strong revenue growth rate of 98.32% from 2023 to 2024, indicating positive momentum. However, the company remains unprofitable with a negative EBIT margin and net profit margin due to significant operating losses.

Balance Sheet

The company has a very high debt-to-equity ratio of 11.82, indicating high leverage and risk. The equity ratio is low at 6.0%, suggesting limited equity buffer, which might pose financial risk.

Cash Flow

While there is an improvement in operating cash flow, the free cash flow remains negative, reflecting ongoing cash burn. The operating cash flow to net income ratio is negative, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.66B	6.93B	4.59B	2.31B	1.51B	1.02B
Gross Profit	4.76B	4.42B	3.09B	1.29B	661.01M	304.91M
EBITDA	-317.43M	-2.40B	59.13M	715.00M	843.00M	638.00M
Net Income	-949.00M	-2.50B	-255.50M	-2.45B	-1.89B	-2.01B
Balance Sheet
Total Assets	7.04B	6.51B	5.89B	5.83B	5.61B	3.51B
Cash, Cash Equivalents and Short-Term Investments	1.98B	1.58B	1.36B	1.17B	2.85B	1.14B
Total Debt	3.20B	2.94B	4.17B	4.37B	3.67B	1.46B
Total Liabilities	4.40B	4.30B	5.53B	5.30B	4.15B	1.85B
Stockholders Equity	2.64B	2.22B	353.31M	524.77M	1.46B	1.66B
Cash Flow
Free Cash Flow	0.00	-1.73B	-1.90B	-4.60B	-2.92B	-3.28B
Operating Cash Flow	0.00	-1.71B	-1.90B	-4.59B	-2.90B	-3.25B
Investing Cash Flow	0.00	-33.30M	-29.76M	-81.50M	-79.86M	-160.32M
Financing Cash Flow	0.00	2.01B	2.06B	2.96B	4.66B	3.46B

3-D Matrix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 228.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7777, the sentiment is Positive. The current price of 228 is above the 20-day moving average (MA) of 218.85, above the 50-day MA of 209.20, and above the 200-day MA of 151.28, indicating a bullish trend. The MACD of 9.65 indicates Negative momentum. The RSI at 55.40 is Neutral, neither overbought nor oversold. The STOCH value of 55.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7777.

3-D Matrix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
5187	78 Outperform	¥9.11B	12.21		3.73%	3.38%	88.65%
7792	77 Outperform	¥13.81B	11.04		1.95%	12.36%	38.55%
7963	75 Outperform	¥8.31B	10.75		2.08%	9.07%	43.42%
6678	74 Outperform	¥16.59B	15.92		3.52%	-8.07%	-38.21%
7600	56 Neutral	¥14.38B	10.23		2.76%	4.84%	-148.94%
7777	51 Neutral	¥25.82B	―	-184.59%	―	51.11%	-606.19%
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%